Abstract

Mastitis imposes considerable and recurring economic losses on the dairy industry worldwide. The main objective of this study was to estimate herd-level costs incurred by expenditures and production losses associated with mastitis on Canadian dairy farms in 2015, based on producer reports. Previously, published mastitis economic frameworks were used to develop an economic model with the most important cost components. Components investigated were divided between clinical mastitis (CM), subclinical mastitis (SCM), and other costs components (i.e., preventive measures and product quality). A questionnaire was mailed to 374 dairy producers randomly selected from the (Canadian National Dairy Study 2015) to collect data on these costs components, and 145 dairy producers returned a completed questionnaire. For each herd, costs due to the different mastitis-related components were computed by applying the values reported by the dairy producer to the developed economic model. Then, for each herd, a proportion of the costs attributable to a specific component was computed by dividing absolute costs for this component by total herd mastitis-related costs. Median self-reported CM incidence was 19 cases/100 cow-year and mean self-reported bulk milk somatic cell count was 184,000 cells/mL. Most producers reported using post-milking teat disinfection (97%) and dry cow therapy (93%), and a substantial proportion of producers reported using pre-milking teat disinfection (79%) and wearing gloves during milking (77%). Mastitis costs were substantial (662 CAD per milking cow per year for a typical Canadian dairy farm), with a large portion of the costs (48%) being attributed to SCM, and 34 and 15% due to CM and implementation of preventive measures, respectively. For SCM, the two most important cost components were the subsequent milk yield reduction and culling (72 and 25% of SCM costs, respectively). For CM, first, second, and third most important cost components were culling (48% of CM costs), milk yield reduction following the CM events (34%), and discarded milk (11%), respectively. This study is the first since 1990 to investigate costs of mastitis in Canada. The model developed in the current study can be used to compute mastitis costs at the herd and national level in Canada.

Highlights

  • Mastitis imposes considerable economic losses on the dairy industry all over the world

  • Selected factors were those associated with current expenditures for mastitis treatment and control and mastitis-associated output losses which could be readily estimated by dairy producers, and included factors related to: drugs, discarded milk, veterinary services, labor, product quality, diagnostic, culling, materials and investments

  • Mean self-reported bulk milk SCC (BMSCC) was 184,000 cells/mL (SD: 69,000 cells/mL; Figure 2), and 67% of respondents participated in dairy herd improvement (DHI)

Read more

Summary

Introduction

Mastitis imposes considerable economic losses on the dairy industry all over the world. This economic burden is due to the additional expenditures on mastitis prevention and treatment, and to the losses due to various factors including reduced milk production, culling and discarded milk. These mastitisrelated expenditures and production losses constitute the basic components of the mastitis economic model proposed by Halasa et al [1]. Clinical mastitis (CM) needs to be detected and treated by the farm personnel, which requires time and drugs, and will result in further discarded milk due to drug withdrawal time. Preventive measures are increasingly adopted by producers to help improve udder health during both lactation and dry periods [2]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.